Bayer Enters Pivotal Stretch as ASCO Pipeline Data Collides with CFO Handover

The coming days bring two closely watched events for Bayer that could shape the stock’s trajectory for weeks. On May 31, the company presents updated clinical data from its lead oncology candidate Sevabertinib at the ASCO annual meeting. The very next day, June 1, Judith Hartmann formally takes over as chief financial officer, replacing the retiring Wolfgang Nickl. Neither event will be judged in isolation, but together they offer the first concrete test of Bayer’s dual narrative: a pharma pipeline seeking a breakthrough and a new finance chief expected to drive sharper capital discipline.

The stock closed the week at €36.48, down 3.57% on the final trading day and roughly 5% lower over the past seven days. That leaves the share price about 5.8% below its 50-day moving average and miles from the 52-week high of €49.17. The market is clearly waiting for catalysts rather than rewarding past performance.

Sevabertinib Takes Centre Stage at ASCO

Bayer is presenting 16 abstracts across six cancer indications at the Chicago conference, showcasing the breadth of its oncology pipeline. The marquee entry is Sevabertinib, developed under the brand HYRNUO, for advanced HER2-mutated non-small cell lung cancer. The company will release updated safety and efficacy data from the SOHO-01 study on May 31 — early results from the Phase I/II trial’s Cohort F, which already secured the FDA’s priority review status in mid-May as a potential first-line therapy.

Full data remain incomplete, making the ASCO readout the first real glimpse for investors. Beyond Sevabertinib, Bayer is also highlighting Xofigo in kidney cancer and breast cancer with bone metastases, Vitrakvi for TRK fusion tumours, and Stivarga in a Phase II trial for HPV-associated malignancies. The pipeline’s breadth is on display, but the weight is squarely on Sevabertinib’s shoulders.

Should investors sell immediately? Or is it worth buying Bayer?

Hartmann Steps into the CFO Role

Judith Hartmann has been on the board since March 1, but only now assumes full responsibility as chief financial officer. Her arrival comes at a time when the market is scrutinising cost management, capital allocation, and operational efficiency. Hartmann’s résumé includes finance chief roles at Engie (where she was also deputy CEO) and Bertelsmann, credentials that fuel expectations she will bring a more hands-on approach to setting priorities.

The transition is not merely procedural. Wolfgang Nickl’s retirement closes a chapter, and Hartmann’s first public remarks on financial priorities — whether on cost targets, investment plans, or balance sheet strategy — could provide the directional signal the stock currently lacks. For now, the shares remain hostage to the weak prior week and sector-wide themes.

Pharma Weakness Weighs on Group Performance

The ASCO presentation lands against a mixed quarterly backdrop. Bayer’s pharmaceuticals division posted a 7.5% decline in EBITDA before special items to €1.242 billion in the first quarter, hurt by patent expirations on Xarelto and generic competition to Eylea. Group-level figures looked healthier: revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.405 billion, while EBITDA climbed 9.0% to €4.453 billion. Bayer reaffirmed its full-year guidance on May 12.

One area of persistent strain is free cash flow, which sank to minus €2.32 billion, still deep in the red after payments to resolve litigation. That underscores why the new CFO’s approach to cash management and legal provisions will be closely watched.

External Pressures: Regulation, Competitors and Pensions

The agricultural business faces renewed scrutiny after a study in Science highlighted a sharp rise in worldwide pesticide toxicity between 2013 and 2019, keeping regulatory risk from biodiversity and plant-protection rules firmly on the radar. Meanwhile, ASCO is not just Bayer’s stage: rivals Novartis and Pfizer are also presenting new oncology data, shaping sentiment across the healthcare sector even if their readouts have no direct implications for Bayer.

Bayer at a turning point? This analysis reveals what investors need to know now.

On the balance-sheet front, broader DAX trends offer modest relief. According to Willis Towers Watson, pension obligations at large German companies fell to €298 billion at the end of 2025, helped by a higher average discount rate of 4.10%. For Bayer, this is no near-term share price driver, but it eases one structural liability.

A Week of Decision Points

Between the Sevabertinib data on May 31 and Hartmann’s first day as CFO on June 1, Bayer faces a rare alignment of pipeline progress and leadership change. The ASCO presentation will test whether the oncology story can regain credibility after a quiet period. And Hartmann’s early signals on efficiency and capital allocation will tell investors how seriously the new management takes margin improvement. Without a clear positive from either, the stock looks set to remain stuck in the shadow of its recent losses and the broader legal and regulatory overhang.

Ad

Bayer Stock: New Analysis - 1 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER | boerse | 69459079 |